<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011234515
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Allocar
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FINASTERIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        90.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QD11AX10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Allocar contains a medicine called Finasteride. This belongs to a group of medicines called &lsquo;5alpha reductase inhibitors.</p><p>Allocar shrinks the prostate gland in men when it is swollen. The prostate gland is found underneath the bladder (but only in men). It produces the fluid found in semen. A swollen prostate gland can lead to a condition called &lsquo;benign prostatic hyperplasia&rsquo; or BPH.</p><p><strong>What is BPH? </strong></p><p>If you have BPH it means that your prostate gland is swollen. It can press on the tube that urine passes through, on its way out of your body.</p><p>This can lead to problems such as:</p><p>&bull;&nbsp;&nbsp;&nbsp; feeling like you need to pass urine more often, especially at night.</p><p>&bull;&nbsp;&nbsp;&nbsp; feeling that you must pass urine right away.</p><p>&bull;&nbsp;&nbsp;&nbsp; finding it difficult to start passing urine.</p><p>&bull;&nbsp;&nbsp;&nbsp; when you pass urine the flow of urine is weak</p><p>&bull;&nbsp;&nbsp;&nbsp; when you pass urine, the flow stops and starts.</p><p>&bull;&nbsp;&nbsp;&nbsp; feeling that you cannot empty your bladder completely in some men, BPH can lead to more serious problems, such as:</p><p>&bull;&nbsp;&nbsp;&nbsp; urinary tract infections</p><p>&bull;&nbsp;&nbsp;&nbsp; a sudden inability to pass urine</p><p>&bull;&nbsp;&nbsp;&nbsp; the need for surgery</p><p><strong>What else should you know about BPH? </strong></p><p>&bull;&nbsp;&nbsp;&nbsp; BPH is not cancer and does not lead to cancer, but the two conditions can be present at the same time.</p><p>&bull;&nbsp;&nbsp;&nbsp; Before you start Allocar, your doctor will do some simple tests to check whether you have prostate cancer.</p><p>Talk to your doctor if you have any questions about this</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are a woman (because this medicine is for men)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic (hypersensitive) to finasteride or any of the other ingredients of this medicine (listed in Section 6).</p><p>Do not take Allocar if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist.</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Allocar if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your partner is pregnant or planning to become pregnant. You should use a condom or other barrier method of contraception when taking Allocar. This is because your semen could contain a tiny amount of the drug and may affect the normal development of the baby&rsquo;s sex organs.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are going to have a blood test called PSA. This is because Allocar can affect the results of this test.</p><p>If you are not sure, talk to your doctor or pharmacist before taking Allocar.</p><p>Mood alterations and depression</p><p>Mood alterations such as depressed mood, depression and, less frequently, suicidal thoughts have been reported in patients treated with Allocar. If you experience any of these symptoms contact your doctor for further medical advice as soon as possible.</p><p><strong>Children </strong></p><p>Allocar should not be used in children.</p><p>Taking other medicines</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Allocar does not usually affect other medicines.</p><p><strong>Taking Allocar with food and drink </strong></p><p>Allocar can be taken with or without food.</p><p>Pregnancy and breast feeding</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Allocar should not be taken by women.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not touch crushed or broken Allocar tablets if you are a woman who is pregnant or planning to become pregnant (whole tablets are coated to stop contact with the medicine during normal use). This is because this medicine may affect the normal development of the baby&rsquo;s sex organs.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; If a woman who is pregnant comes into contact with crushed or broken Allocar tablets, speak to your doctor.</p><p><strong>Driving and using machines </strong></p><p>Allocar is not likely to affect you being able to drive, use tools or machines.</p><p>Allocar contains</p><p>Lactose. This is a type of sugar. If you have ever been told by your doctor that you cannot tolerate or digest some sugars (have an intolerance to some sugars), talk to your doctor or pharmacist before taking this medicine.</p><p>Allocar contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Taking this medicine</p><p>&bull;&nbsp;&nbsp;&nbsp; The usual dose is one tablet each day.</p><p>&bull;&nbsp;&nbsp;&nbsp; Take this medicine by mouth.</p><p>&bull;&nbsp;&nbsp;&nbsp; Your doctor may prescribe Allocar along with another medicine (called doxazosin) to help control your BPH.</p><p><strong>If you take more Allocar than you should </strong></p><p>If you take too many tablets by mistake, contact your doctor immediately.</p><p>If you forget to take Allocar</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you forget to take a tablet, skip the missed dose.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the next dose as usual.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>If you stop taking Allocar</p><p>Your condition may show an early improvement after taking Allocar. However, it may take at least six months for the full effect to develop. It is important to keep taking Allocar for as long as your doctor tells you, even if you do not feel any benefit straight away.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>Allergic reactions</p><p>Stop using Allocar and immediately contact a doctor if you experience any of the following symptoms:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of face, lips, tongue or throat, difficulty swallowing and breathing difficulties</p><p>(angioedema)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rashes, itching, or lumps under your skin (hives).</p><p><strong>Other side effects may include: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may be unable to have an erection (impotence)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may have less desire to have sex.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may have problems with ejaculation, for example a decrease in the amount of semen released during sex. This decrease in the amount of semen does not appear to affect normal sexual function.</p><p>These side effects above may disappear after a while if you continue taking Allocar. If not, they usually resolve after stopping Allocar. Other side effects reported in some men are:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast swelling or tenderness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations (feeling your heartbeat)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the way your liver is working, which can be shown by a blood test.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in your testicles</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in semen</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An inability to have an erection which may continue after stopping the medication.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Male infertility and/or poor quality of semen. Improvement in the quality of the semen has been reported after stopping medication.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in sex drive that may continue after stopping the medication.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with ejaculation that may continue after stopping the medication.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety</p><p>You should promptly report to your doctor any changes in your breast tissue such as lumps, pain, enlargement or nipple discharge as these may be signs of a serious condition, such as breast cancer. If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. It will help if you make a note of what happened, when it started and how long it lasted.</p><p><strong>What else should you know about Allocar? </strong></p><p>Allocar (finasteride) is not licensed to treat prostate cancer. Information collected for a clinical trial in men taking finasteride for 7 years showed:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The number of men who developed prostate cancer was lower in men taking finasteride compared with those taking nothing.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The number of men who had a high score in a tumour grading system was higher in some of those taking finasteride compared to those taking nothing.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The effect of long-term use of finasteride on tumours of this kind is not known.</p><p>If you would like further information about the tumour grading system or this trial, please talk to your doctor</p><p>Reporting of side effect</p><p>&bull; If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Finasteride.</p><p>Each film coated tablet contains Finasteride Ph.Eur 5 mg.</p><p><strong>The other ingredients are </strong>cellulose microcrystalline, Lactose monohydrate, starch pregelatinized Sodium starch glycolate, Docusate sodium, Magnesium stearate.</p><p><strong>Film Coating Composition: </strong>HPMC 2910/Hypromellose 6cP, Titanium Dioxide, FD&amp;C Blue #2/Indigo Carmine Aluminum Lake, Talc, Iron Oxide Yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Blue colour, round film coated tablets, debossed with 'H' on one side and '37' on other side.

How supplied:

Finasteride Tablets 5 mg are supplied in Blister pack.

Allocar – contains Box of 30 blister tablets (3 x 10’s) Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder and Manufacturer Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter,</p><p>Riyadh 12629, Saudi Arabia</p><p>Tel: +966 11 226 8850</p><p>Manufacturer</p><p>Hetero Lab Limited Unit III, Telangana, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                    Last revised in October 2023, Version 1 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">یحتوي ألوكار على مادة فعالة تسمى فیناستراید. ینتمي فیناستراید إلى مجموعة من الأدویة تسمى &quot;مثبطات اختزال ٥-ألفا&quot; النوع الثاني .&nbsp;</p><p dir="RTL">یعمل ألوكار أقراص على انكماش غدة البروستاتا عند الرجال وذلك عندما تكون متورمة .توجد غدة البروستاتا تحت المثانة (ولكن فقط عند الرجال.) حیث تتمثل وظیفتھا في انتاج السائل الموجود في السائل المنوي. یمكن أن تؤدي غدة البروستاتا المنتفخة إلى حالة تسمى &quot;تضخم البروستاتا الحمید&quot; أو BPH .</p><p dir="RTL"><strong>ما ھو تضخم البروستاتا الحمید؟ </strong></p><p dir="RTL">إذا كنت مصاباً بتضخم البروستاتا الحمید ، فھذا یعني أن غدة البروستاتا متورمة .ویم كن أن یقوم ھذا التورم بالضغط على الأنبوب الذي یمر من خلالھ البول ، في طریقھ للخروج من جسمك.&nbsp;</p><p dir="RTL">ھذا یمكن أن یؤدي إلى مشاكل مثل:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالحاجة إلى التبول أكثر من مرة ، خاصة في اللیل .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضرورة التبول على الفور .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجد صعوبة في التبول.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند التبول یكون تدفق البول ضعیفا ً.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند التبول یتوقف التدفق ویبدأ.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم قدرتك على إفراغ مثانتك بالكامل .</p><p dir="RTL">یمكن أن یؤدي تضخم البروستاتا الحمید إلى مشاكل أكثر خطورة في بعض الرجال ، مثل:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التھابات المسالك البولیة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور المفاجئ&nbsp; بعدم القدرة على التبول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحاجة إلى اجراء جراحة .</p><p dir="RTL"><strong>ما الذي یجب أن تعرفھ أیضًا عن تضخم البروستاتا الحمید؟ </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا یعتبر تضخم البروستاتا الحمید سرطاناً ولا یؤدي إلى الإصابة بالسرطان ، ولكن یمكن أن تكون الحالتان موجودتان في نفس الوقت الوقت .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل أن تبدأ بالعلاج بتناول ألوكار ، سیقوم طبیبك بإجراء بعض الاختبارات البسیطة للتحقق مما إذا كنت مصاباً بسرطان البروستاتا.</p><p dir="RTL">تحدث إلى طبیبك إذا كان لدیك أي أسئلة حول ھذا الموضوع.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أقراص&nbsp; </strong>یجب عدم تناول ألوكار أقراص في الحالات التالیة:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت امرأة (لأن ھذا الدواء للرجال)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسیة (الحساسیة الشدیدة) لمادة فیناستراید أو أي من المكونات الأخرى لھذا الدواء (المدرجة في القسم ٦) .</p><p dir="RTL">یجب عدم تناول ألوكار إذا كان أي مما سبق ینطبق علیك. وإذا لم تكن متأكًدًا ، تحدث إلى طبیبك أو الصیدلي.</p><p dir="RTL"><strong>التحذیرات والإحتیاطات </strong></p><p dir="RTL">تحدث إلى طبیبك أو الصیدلي قبل تناول ألوكار في االحالات التالیة :</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت شریكتك حامل أو تخطط للحمل. یجب علیك استخدام الواقي الذكري أو أي وسیلة أخرى لمنع الحمل عند تناول ألوكار. وذلك لأن السائل المنوي الخاص بك یمكن أن یحتوي على كمیة ضئیلة من الدواء وقد یؤثر على النمو الطبیعي للأعضاء التناسلیة لدى الطفل.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستخضع لفحص دم لسرطان البروستاتا یسمى PSA (مستضد البروستاتا النوعي). ھذا لأن ألوكار یمكن أن یؤثر على نتیجة ھذا الاختبار.</p><p dir="RTL">إذا لم تكن متأكًدًا ، تحدث إلى طبیبك أو الصیدلي قبل تناول ألوكار.</p><p dir="RTL"><strong>التغیرات المزاجیة والاكتئاب&nbsp; </strong></p><p dir="RTL">تم الإبلاغ عن تغیرات في الحالة المزاجیة مثل المزاج المكتئب والاكتئاب ، والأفكار الانتحاریة (بمعدلات منخفضة) وذلك في المرضى الذین عولجوا بـاستخدام ألوكار. إذا واجھت أیًا من ھذه الأعراض ، فتوقف عن تناول ألوكار واتصل بطبیبك للحصول على مزید من النصائح الطبیة في أقرب وقت ممكن.&nbsp;</p><p dir="RTL"><strong>الأطفال&nbsp; </strong></p><p dir="RTL">لا ینبغي أن تستخدم ألوكار للأطفال.&nbsp;</p><p dir="RTL"><strong>تناول الأدویة الأخرى و</strong> <strong>ألوكار </strong></p><p dir="RTL">أخبر طبیبك أو الصیدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدویة أخرى .عادة لا یؤثر ألوكار على الأدویة الأخرى.</p><p dir="RTL"><strong>تناول ألوكار مع الطعام والشراب </strong>یمكن تناول ألوكار مع الطعام أو بدونھ.</p><p dir="RTL"><strong>الحمل والرضاعة الطبیعیة</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ینبغي استخدام ألوكار من قبل النساء.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تلمس أقراص ألوكار المكسورة أو المنقسمة إذا كنت امرأة حامل أو تخططین للحمل (الأقراص كاملة مغلفة لمنع ملامسة الدواء أثناء الاستخدام العادي.) وذلك لأن ھذا الدواء قد یؤثر على الأعضاء التناسلیة للطفل.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرضت امرأة حامل لأقراص ألوكار مكسورة أو مسحوقة ، تحدث إلى طبیبك.</p><p dir="RTL"><strong>القیادة واستخدام الألات </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لیس من المحتمل أن یؤثر ألوكار على قدرتك على القیادة أو استخدام الأدوات أو الآلات.&nbsp;</p><p dir="RTL"><strong>محتوي</strong> <strong>ألوكارمن اللاكتوز </strong></p><p dir="RTL">إذا أخبرك طبیبك أنھ لا یمكنك تحمل أو ھضم بعض السكریات ، فاتصل بطبیبك قبل تناول ھذا المنتج الطبي.&nbsp;</p><p dir="RTL"><strong>محتوي</strong> <strong>ألوكار من الصودیو م </strong></p><p dir="RTL">یحتوي ھذا الدواء على أقل من ۱ ملیمول صودیوم ( ۲۳ ملجرام) لكل قرص ، وھذا یعني بشكل أساسي &quot;خالٍ من الصودیوم .&quot;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول ھذا الدواء تمامًا كما أخبرك طبیبك أو الصیدلي. استشر طبیبك أو الصیدلي إذا لم تكن متأكًدًا.&nbsp;</p><p dir="RTL"><strong>طریقة تناول ھذا الدواء </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة ھي قرص واحد كل یوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول ھذا الدواء عن طریق الفم.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد یصف طبیبك عقار ألوكار مع دواء آخر (یسمى دوكسازوسین) للمساعدة في السیطرة على تضخم البروستاتا الحمید لدیك.</p><p dir="RTL"><strong>تناول جرعة زائدة من ألوكار أكثر مما ینبغي </strong></p><p dir="RTL">إذا تناولت عدًدًا كبیرًا جًدًا من الأقراص عن طریق الخطأ ، فاتصل بطبیبك على الفور.&nbsp;</p><p dir="RTL"><strong>إذا نسیت أن تتناول ألوكار </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا نسیت تناول قرص ، فتجاوز الجرعة الفائتة .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول الجرعة التالیة كالمعتاد.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول جرعة مضاعفة لتعویض الجرعة المنسیة.&nbsp;</p><p dir="RTL"><strong>التوقفت عن تناول ألوكا ر </strong></p><p dir="RTL">قد تظھر حالتك تحسنًا مبكرًا بعد تناول ألوكار. ومع ذلك ، قد یستغرق الأمر ستة أشھر على الأقل حتى یتطور التأثیر الكامل. من المھم أن تستمر في تناول ألوكار طالما أخبرك طبیبك ، حتى لو لم تشعر بأي فائدة على الفور.&nbsp;</p><p dir="RTL">إذا كان لدیك أي أسئلة أخرى حول استخدام ھذا الدواء ، اسأل طبیبك أو الصیدلي.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جمیع الأدویة ، یمكن أن یسبب ھذا الدواء آثارًا جانبیة ، على الرغم من عدم حدوثھا لدى الجمیع. قد تحدث الآثار الجانبیة التال یة مع استخدام ھذا الدواء:&nbsp;</p><p dir="RTL"><strong>ردود الفعل التحسسیة </strong></p><p dir="RTL">توقف عن تناول ألوكار أقراص واتصل بالطبیب فورًا إذا واجھت أیاً من الأعراض التالیة:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجھ والشفتین واللسان أو الحلق وصعوبة البلع وصعوبة التنفس (وذمة وعائیة).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أو حكة أو كتل تحت الجلد (الشرى) .</p><p dir="RTL"><strong>قد تشمل الآثار الجانبیة الأخرى:&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد لا تتمكن من الانتصاب (الضعف الجنسي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد یكون لدیك رغبة أقل في ممارسة الجن س.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد یكون لدیك مشاكل في القذف ، على سبیل المثال انخفاض في كمیة السائل المنوي الذي یتم إطلاقھ أثناء ممارسة الجنس. لا یبدو أن ھذا الانخفاض في كمیة السائل المنوي یؤثر على الوظیفة الجنسیة الطبیعیة.&nbsp;</p><p dir="RTL">قد تختفي ھذه الآثار الجانبیة المذكورة أعلاه بعد فترة إذا واصلت تناول ألوكار. إذا لم یكن الأمر كذلك ، فعادة ما یتم حلھا بعد التوقف ألوكار.&nbsp;</p><p dir="RTL"><strong>الآثار الجانبیة الأخرى التي تم الإبلاغ عنھا لدى بعض الرجال ھي:&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ أو إیلام الثدي .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخفقان (الشعور بضربات قلبك) .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغیرات في طریقة عمل الكبد ، والتي یمكن أن تظھر من خلال فحص الدم .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الخصیتین.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظھور دم في السائل المنوي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على الانتصاب الذي قد یستمر بعد التوقف عن تناول الدواء .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقم عند الذكور و / أو انخفاض جودة السائل المنوي. تم الإبلاغ عن تحسن في جودة السائل المنوي بعد التوقف عن تناول الدواء .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كآبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الدافع الجنسي الذي قد یستمر بعد التوقف عن تناول الدواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل القذف التي قد تستمر بعد التوقف عن تناول الدواء .</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق .</p><p dir="RTL">یجب علیك إبلاغ طبیبك على الفور بأي تغییرات في أنسجة الثدي مثل ظھور الكتل ، والألم ، والتضخم أو إفرازات الحلمة لأن ھذه قد تكون علامات على حالة خطیرة ، مثل سرطان الثدي.&nbsp;</p><p dir="RTL">إذا تفاقمت أي من الآثار الجانبیة ، أو إذا لاحظت أي آثار جانبیة غیر مدرجة في ھذه النشرة ، فیرجى إخبار طبیبك أو الصیدلي. سوف یساعدك إذا قمت بتدوین ما حدث ، ومتى بدأ ، ومدة استمراره.&nbsp;</p><p dir="RTL"><strong>ما الذي یجب أن تعرفھ أیضًا عن ألوكار أقراص؟ </strong></p><p dir="RTL">غیر مرخص لاستخدام ألوكار (فیناستراید) لعلاج سرطان البروستاتا. أظھرت المعلومات التي تم جمعھا من التج ارب السریریة على الرجال الذین تناولوا فیناستراید لمدة ۷ سنوات ما یلي:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان عدد الرجال الذین أصیبوا بسرطان البروستاتا أقل لدى الرجال الذین یتناولون الفیناستراید مقارنة مع أولئك الذین لا یتناولونھ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان عدد الرجال الذین حصلوا على درجة عالیة في نظام تصنیف الأورام أعلى لدى بعض الذین تناولوا فیناستراید مقارنةً بأولئك الذین لا یتناولونھ.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن تأثیر استخدام الفیناستراید على المدى الطویل على أورام من ھذا النوع غیر معروف.</p><p dir="RTL">إذا كنت ترغب في الحصول على مزید من المعلومات حول نظام تصنیف الورم أو ھذه التجربة ، فیرجى التحدث مع طبیبك.</p><p dir="RTL"><strong>التبلیغ عن الأعراض الجانبیة&nbsp; </strong></p><p dir="RTL">إن كان لدیك أعراض جانبیة أو لاحظ ت أعراض جانبیة غیر مذكورة في ھذه النشرة، فضلًا&nbsp; ابلغ الطبیب أوالصیدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یجب أن یحفظ في درجة حرارة أقل من ۳۰ درجة مئویة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; یجب التخزین في العلبة الأصلیة للحمایة من الرطوبة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ ھذا الدواء بعیًدًا عن رؤیة ومتناول أیدي الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم ھذا الدواء بعد تاریخ انتھاء الصلاحیة المذكور على العبوة .یشیر تاریخ انتھاء الصلاحیة إلى الیوم الأخیر من الشھر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدویة في میاه الصـرف الصـحي أو النفایات المنزلیة. اسـأل الصـیدلي عن كیفیة التخلص من الأدویة التي لم تعد تسـتخدمھا. س ـتسـاعد ھذه الإجراءات في حمایة البیئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما یحتویھ ألوكار أقراص&nbsp; </strong></p><p dir="RTL">المادة الفعالة&nbsp; لألوكار أقراص ھي فیناستیراید&nbsp;</p><p dir="RTL">یحتوي كل قرص مغلف على 5 ملجرام فیناستیراید المتوافق مع دستور الأدویة الأوروبي.</p><p dir="RTL"><strong>الصواغات الأخرى: </strong></p><p dir="RTL">السلیلوز دقیق التبلور ، اللاكتوز أحادي ا لھیدرات ، النشا الصودیوم جلایكولات ، دوكوسات الصودیوم ، وستیارات الماغنیسیوم.</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الكسوة الخارجیة: </strong></p><p dir="RTL">ھیبرومیلوزHPMC 2910) 6cP) و ثاني أكسید التیتانیوم وأكسید الحدید الأصفر وأكسید الحدید الأصف ر و تلك و صبغة زرقاء FD &amp; C Blue # 2 / Indigo Carmine Aluminium Lake .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كیف یبدو ألوكار أقراص ومحتویات العبوة </strong></p><p dir="RTL">أقراص مستدیرة الشكل مطلیة باللون الأزرق ، ، منقوش علیھا حرف&quot; H&quot; على جانب واحد و&quot; ۳۷&quot; على الجانب الآخ ر <strong>كیف تتوفر: </strong></p><p dir="RTL">یتم توفیر أقراص فیناستراید ٥ ملجرام في عبوة تحتوي على شرائط .</p><p dir="RTL">تحتوي علبة ألوكار ٥ ملجرام على شرائط بھا ۳x ۱۰ أقراص.&nbsp;</p><p dir="RTL">قد لا تتوافر جمیع العبوات في السوق.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة أماروكس السعودیة الصناعية</strong><br />&nbsp; شارع الجامعة &ndash; الملز &ndash; الریاض 12629 المملكة العربیة السعودیة.</p><p dir="RTL">&nbsp; تلیفون: 0588 622 11 669 +<br />&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">هيتيرولاب المحدودة، الوحدة الثالثة، تيلانجانا، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة ھذه النشرة في اكتوبر ۲۰۲۳ ، نسخة ۱
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Allocar 1 (Finasteride Tablets 1mg)  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated  tablet contains Finasteride Ph.Eur 1mg.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Brown colour, round film coated tablets, debossed with 'H' on one side and '36' on other side  
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Allocar is indicated for the treatment of men with male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss.&nbsp;</p><p>Allocar is not indicated for use in women or children and adolescents.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u> <strong>&nbsp;</strong></p><p>The recommended dosage is one 1 mg tablet daily. Allocar may be taken with or without food.&nbsp;</p><p>There is no evidence that an increase in dosage will result in increased efficacy.&nbsp;</p><p>Efficacy and duration of treatment should continuously be assessed by the treating physician. Generally, three to six months of once daily treatment are required before evidence of stabilisation of hair loss can be expected. Continuous use is recommended to sustain benefit. If treatment is stopped, the beneficial effects begin to reverse by six months and return to baseline by 9 to 12 months.&nbsp;</p><p>Method of administration&nbsp;</p><p>Crushed or broken tablets of &#39; Allocar &#39; should not be handled by women when they are or may potentially be&nbsp; pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male foetus (see section 4.6 Fertility, pregnancy and lactation). Allocar tablets are coated to prevent contact with the active ingredient during normal handling, provided that the tablets are not broken or crushed.&nbsp;</p><p>Patients with renal impairment&nbsp;</p><p>No dosage adjustment is required in patients with renal insufficiency.&nbsp;</p><p>No data are available on the concomitant use of Allocar and topical minoxidil in male pattern hair loss.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Contraindicated in women: see section 4.6 'Fertility, pregnancy and lactation' and section 5.1 'Pharmacodynamic properties'.  
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.  
Allocar is not indicated for use in women or children and adolescents.  
Allocar should not be taken by men who are taking 'Proscar' (finasteride 5 mg) or any other 5αreductase inhibitor for benign prostatic hyperplasia or any other condition.  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Paediatric population</u>&nbsp;</p><p>Allocar should not be used in children. There are no data demonstrating efficacy or safety of finasteride in children under the age of 18. <u>Effects on Prostate Specific Antigen (PSA)</u><strong> </strong>&nbsp;</p><p>In clinical studies with Allocar in men 18-41 years of age, the mean value of serum prostatespecific antigen (PSA) decreased from 0.7 ng/ml at baseline to 0.5 ng/ml at month 12. Doubling the PSA level in men taking Allocar should be considered before evaluating this test result.&nbsp;</p><p><u>Effects on fertility</u>&nbsp;</p><p>See section 4.6 Fertility, pregnancy and lactation&nbsp; <u>Hepatic impairment</u>&nbsp;</p><p>The effect of hepatic insufficiency on the pharmacokinetics of finasteride has not been studied.&nbsp;</p><p><u>Breast Cancer</u>&nbsp;</p><p>Breast cancer has been reported in men taking finasteride 1 mg during the post-marketing period. Physicians should instruct their patients to promptly report any changes in their breast tissue such as lumps, pain, gynaecomastia or nipple discharge.&nbsp;</p><p><u>Mood alterations and depression</u>&nbsp;</p><p>Mood alterations including depressed mood, depression and, less frequently, suicidal ideation have been reported in patients treated with finasteride 1 mg. Patients should be monitored for psychiatric symptoms and if these occur, treatment with finasteride should be discontinued and the patient advised to seek medical advice. <u>Lactose intolerance</u>&nbsp;</p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.&nbsp;</p><p><u>Sodium</u>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &#39;sodium-free&#39;.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Finasteride is metabolised primarily via, but does not affect, the cytochrome P450 3A4 system. Although the risk for finasteride to affect the pharmacokinetics of other drugs is estimated to be small, it is probable that inhibitors and inducers of cytochrome P450 3A4 will affect the plasma concentration of finasteride. However, based on established safety margins, any increase due to concomitant use of such inhibitors is unlikely to be of clinical significance.&nbsp;</p><p>Interaction studies have only been performed in adults<strong> </strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u>&nbsp;</p><p>Allocar is contra-indicated for use in women due to the risk in pregnancy. Because of the ability of type II 5&alpha;- reductase inhibitors to inhibit conversion of testosterone to dihydrotestosterone (DHT) in some tissues, these drugs, including finasteride, may cause abnormalities of the external genitalia of a male foetus when administered to a pregnant woman.&nbsp;</p><p>Exposure to finasteride: risk to male foetus&nbsp;</p><p>A small amount of finasteride, less than 0.001% of the 1 mg dose per ejaculation, has been detected in the seminal fluid of men taking Allocar. Studies in Rhesus monkeys have indicated that this amount is unlikely to constitute a risk to the developing male foetus (see Section 5.3). During continual collection of adverse experiences, post-marketing reports of exposure to finasteride during pregnancy via semen of men taking 1 mg or higher doses have been received for eight live male births, and one retrospectively-reported case concerned an infant with simple hypospadias.</p><p>Causality cannot be assessed on the basis of this single retrospective report and hypospadias is a relatively common congenital anomaly with an incidence ranging from 0.8 to 8 per 1000 live male births. In addition, a further nine live male births occurred during clinical trials following exposure to finasteride via semen, during pregnancy, and no congenital anomalies have been reported.&nbsp;</p><p>Breast-feeding&nbsp;</p><p>It is not known whether finasteride is excreted in human milk.<br /><strong>Fertility </strong>&nbsp;</p><p>Long-term data on fertility in humans are lacking, and specific studies in subfertile men have not been conducted. The male patients who were planning to father a child were initially excluded from clinical trials. Although, animal studies did not show relevant negative effects on fertility, spontaneous reports of infertility and /or poor seminal quality were received post-marketing. In some of these reports, patients had other risk factors that might have contributed to infertility. Normalisation or improvement of seminal quality has been reported after discontinuation of</p><p>finasteride.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Allocar has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions during clinical trials and/or post-marketing use are listed in the table below.&nbsp;</p><p>Frequency of adverse reactions is determined as follows:&nbsp;</p><p>Very Common (&ge; 1/10); Common (&ge; 1/100 to &le; 1/10); Uncommon (&ge; 1/1,000 to &le; 1/100); Rare (&ge;1/10,000 to &le; 1/1,000); Very rare (&lt; 1/10,000); Not known (cannot be estimated from the available data). The frequency of adverse reactions reported during post-marketing use cannot be determined as they are derived from spontaneous reports.&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_352" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:468pt;height:213.75pt;flip:y;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="624" height="285" alt="" vspace="0" hspace="0" border="0" style="width:624px;height:285px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" />&nbsp;</p><p>&dagger; This adverse reaction was identified through post-marketing surveillance but the incidence in randomised controlled Phase III clinical trials (Protocols 087, 089, and 092) was not different between finasteride and placebo.&nbsp;</p><p>Side effects, which usually have been mild, generally have not required discontinuation of therapy.&nbsp;</p><p>Finasteride for male pattern hair loss has been evaluated for safety in clinical studies involving more than 3,200 men.&nbsp;</p><p>In three 12-month, placebo-controlled, double-blind, multicentre studies of comparable design, the overall safety profiles of Allocar and placebo were similar. Discontinuation of therapy due to any clinical adverse experience occurred in 1.7% of 945 men treated with Allocar and 2.1% of 934 men treated with placebo.&nbsp;</p><p>In these studies, the following drug-related adverse experiences were reported in &ge;1% of men treated with Allocar: decreased libido (Allocar, 1.8% vs. placebo, 1.3%) and erectile dysfunction (1.3%, 0.7%). In addition, decreased volume of ejaculate was reported in 0.8% of men treated with Allocar and 0.4% of men treated with placebo.&nbsp;</p><p>Resolution of these side effects occurred in men who discontinued therapy with Allocar and in many who continued therapy. The effect of Allocar on ejaculate volume was measured in a separate study and was not different from that seen with placebo.&nbsp;</p><p>By the fifth year of treatment with Allocar, the proportion of patients reporting each of the above side effects decreased to &lt;0.3%. &nbsp;</p><p>Finasteride has also been studied for prostate cancer risk reduction at 5 times the dosage recommended for male pattern hair loss. In a 7-year placebo-controlled trial that enrolled 18,882 healthy men, of whom 9060 had prostate needle biopsy data available for analysis, prostate cancer was detected in 803 (18.4%) men receiving finasteride 5 mg and 1147 (24.4%) men receiving placebo. In the finasteride 5 mg group, 280 (6.4%) men had prostate cancer with Gleason scores of 7-10 detected on needle biopsy vs. 237 (5.1%) men in placebo group. Of the total cases of prostate cancer diagnosed in this study, approximately 98% were classified as intracapsular (stage T1 or T2). The relationship between long-term use of finasteride 5 mg and tumours with Gleason scores of 7-10 is unknown.&nbsp;</p><p>In addition, the following have been reported in post-marketing use: persistence of sexual dysfunction (decreased libido, erectile dysfunction and ejaculation disorder) after discontinuation of treatment with Allocar; male breast cancer (see 4.4 Special warnings and precautions for use). &nbsp;Drug-related sexual undesirable effects were more common in the finasteride 1 mg-treated men than the placebotreated men, with frequencies during the first 12 months of 3.8% vs 2.1%, respectively. The incidence of these effects decreased to 0.6% in finasteride 1 mg-treated men over the following four years. Approximately 1% of men in each treatment group discontinued due to drug-related sexual adverse experiences in the first 12 months, and the incidence declined</p><p>thereafter.&nbsp;</p><p><u>Reporting of suspected adverse reactions</u>&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine. &nbsp;</p><p><strong><em>&bull; </em>Saudi Arabia<em>:</em></strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC) o</p><p>SFDA Call Center: 19999</p><p>o&nbsp; E-mail:npc.drug@sfda.gov.sa o Website:https://ade.sfda.gov.sa/</p><p>o&nbsp; <strong>Other GCC States:</strong></p><p>&nbsp;Please contact the relevant competent authority.<strong> </strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, single doses of finasteride up to 400 mg and multiple doses of finasteride up to 80 mg/day for three months (n=71) did not result in dose-related undesirable effects.&nbsp;</p><p>No specific treatment of overdosage with Allocar is recommended</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: 5&alpha;-reductase inhibitor. ATC code: D11AX10 <strong>Mechanism </strong></p><p>of action &nbsp;</p><p>Finasteride is a competitive and specific inhibitor of type II 5&alpha;-reductase. Finasteride has no affinity for the androgen receptor and has no androgenic, anti-androgenic, oestrogenic, antioestrogenic, or progestational effects. Inhibition of this enzyme blocks the peripheral conversion of testosterone to the androgen DHT, resulting in significant decreases in serum and tissue DHT concentrations. Finasteride produces a rapid reduction in serum DHT concentration, reaching significant suppression within 24 hours of dosing.&nbsp;</p><p>Hair follicles contain type II 5&alpha;-reductase. In men with male pattern hair loss, the balding scalp contains miniaturized hair follicles and increased amounts of DHT. Administration of finasteride decreases scalp and serum DHT concentrations in these men. Men with a genetic deficiency of type II 5&alpha;-reductase do not suffer from male pattern hair loss. Finasteride inhibits a process responsible for miniaturisation of the scalp hair follicles, which can lead to reversal of the balding process.&nbsp;</p><p><u>Clinical efficacy and safety</u>&nbsp;</p><p>Studies in men&nbsp;</p><p>Clinical studies were conducted in 1879 men aged 18 to 41 with mild to moderate, but not complete, vertex hair loss and/or frontal/mid-area hair loss. In the two studies in men with vertex hair loss (n=1553), 290 men completed 5 years of treatment with Allocar vs. 16 patients on placebo. In these two studies, efficacy was assessed by the following methods: (i) hair count in a representative 5.1cm2 area of scalp, (ii) patient self-assessment questionnaire, (iii) investigator assessment using a seven point scale, and (iv) photographic assessment of standardised paired photographs by a blinded expert panel of dermatologists using a seven point scale.&nbsp;</p><p>In these 5- year studies men treated with Allocar improved compared to both baseline and placebo beginning as early as 3 months, as determined by both the patient and investigator assessments of efficacy. With regard to hair count, the primary endpoint in these studies,</p><p>increases compared to baseline were demonstrated starting at 6 months (the earliest time point</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_7027" o:spid="_x0000_s1026" style='width:446.25pt;height:.75pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="56673,95" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_555" o:spid="_x0000_s1027" style='position:absolute;
  width:56673;height:0;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5667375,0" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l5667375,e" filled="f">
  <v:path arrowok="t" textboxrect="0,0,5667375,0"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="597" height="2" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:446.25pt;height:.75pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>assessed) through to the end of the study. In men treated with Allocar these increases were greatest at 2 years and gradually declined thereafter to the end of 5 years; whereas hair loss in the placebo group progressively worsened compared to baseline over the entire 5 year period. In Allocar treated patients, a mean increase from baseline of 88 hairs [p &lt;0.01; 95% CI (77.9, &nbsp;</p><p>97.80; n=433] in the representative 5.1 cm2 area was observed at 2 years and an increase from baseline of 38 hairs [p &lt;0.01; 95% CI (20.8, 55.6); n=219] was observed at 5 years, compared with a decrease from baseline of 50 hairs [p &lt;0.01; 95% CI (-80.5, -20.6);n=47] at 2 years and a decrease from baseline of 239 hairs [p &lt;0.01; 95% CI (-304.4, -173.4); n=15] at 5 years in patients who received placebo. Standardised photographic assessment of efficacy demonstrated that 48% of men treated with finasteride for 5 years were rated as improved, and an additional 42% were rated as unchanged. This is in comparison to 25% of men treated with placebo for 5 years who were rated as improved or unchanged. These data demonstrate that treatment with Allocar for 5 years resulted in a stabilisation of the hair loss that occurred in men treated with placebo.&nbsp;</p><p>An additional 48-week, placebo-controlled study designed to assess the effect of Allocar on the phases of the hair growth cycle (growing phase [anagen] and resting phase [telogen]) in vertex baldness enrolled 212 men with androgenetic alopecia. At baseline and 48 weeks, total, anagen and telogen hair counts were obtained in a 1-cm2 target area of the scalp. Treatment with Allocar led to improvements in anagen hair counts, while men in the placebo group lost anagen hair. At 48 weeks, men treated with Allocar showed net increases in total and anagen hair counts of 17 hairs and 27 hairs, respectively, compared to placebo. This increase in anagen hair count, compared to total hair count, led to a net improvement in the anagen-to-telogen ratio of 47% at 48 weeks for men treated with Allocar, compared to placebo. These data provide direct evidence that treatment with Allocar promotes the conversion of hair follicles into the actively growing phase.&nbsp;</p><p>Studies in women&nbsp;</p><p>Lack of efficacy was demonstrated in post-menopausal women with androgenetic alopecia who were treated with Allocar in a 12 month, placebo-controlled study (n=137). These women did not show any improvement in hair count, patient self-assessment, investigator assessment, or ratings based on standardized photographs, compared with the placebo group</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u>&nbsp;</p><p>Relative to an intravenous reference dose, the oral bioavailability of finasteride is approximately 80%. The bioavailability is not affected by food. Maximum finasteride plasma concentrations are reached approximately two hours after dosing and the absorption is complete after six to eight hours.&nbsp;</p><p><u>Distribution</u>&nbsp;</p><p>Protein binding is approximately 93%. The volume of distribution of finasteride is approximately 76 litres. At steady state following dosing with 1 mg/day, maximum finasteride plasma concentration averaged 9.2 ng/ml and was reached 1 to 2 hours post-dose; AUC (0-24 hr) was 53 ng&bull;hr/ml. Finasteride has been recovered in the cerebrospinal fluid (CSF), but the drug does not appear to concentrate preferentially to the CSF. A small amount of finasteride has also been detected in the seminal fluid of subjects receiving the drug.&nbsp;</p><p><u>Biotransformation</u>&nbsp;</p><p>Finasteride is metabolised primarily via the cytochrome P450 3A4 enzyme subfamily. Following an oral dose of 14Cfinasteride in man, two metabolites of the drug were identified that possess only a small fraction of the 5&alpha;-reductase inhibitory activity of finasteride.&nbsp;</p><p><u>Elimination</u>&nbsp;</p><p>Following an oral dose of 14C-finasteride in man, 39% of the dose was excreted in the urine in the form of metabolites (virtually no unchanged drug was excreted in the urine) and 57% of total dose was excreted in the faeces.&nbsp;</p><p>Plasma clearance is approximately 165 ml/min.&nbsp;</p><p>The elimination rate of finasteride decreases somewhat with age. Mean terminal half-life is approximately 5-6 hours in men 18-60 years of age and 8 hours in men more than 70 years of age. These findings are of no clinical significance and hence, a reduction in dosage in the elderly is not warranted.&nbsp;</p><p><u>Renal impairment</u>&nbsp;</p><p>No adjustment in dosage is necessary in non-dialysed patients with renal impairment.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In general, the findings in laboratory animal studies with oral finasteride were related to the pharmacological effects of 5&alpha;-reductase inhibition.&nbsp;</p><p>Intravenous administration of finasteride to pregnant rhesus monkeys at doses as high as 800 ng/day during the entire period of embryonic and foetal development resulted in no abnormalities in male foetuses. This represents at least 750 times the highest estimated exposure of pregnant women to finasteride from semen. In confirmation of the relevance of the Rhesus model for human foetal development, oral administration of finasteride 2 mg/kg/day (100 times the recommended human dose or approximately 12 million times the highest estimated exposure to finasteride from semen) to pregnant monkeys resulted in external genital abnormalities in male foetuses. No other abnormalities were observed in male foetuses and no finasteride-related abnormalities were observed in female foetuses at any dose.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The other ingredients are: cellulose microcrystalline, Lactose monohydrate, starch pregelatinized&nbsp;&nbsp;&nbsp;&nbsp; Sodium starch glycolate, Docusate sodium, Magnesium stearate Purified water.&nbsp;</p><p>&nbsp; Film Coating Composition: HPMC 2910 Hypromellose Titanium Dioxide, Yellow Iron Oxide, Iron</p><p>Oxide red, -Talc <strong>&nbsp;</strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.<strong> </strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>3 x 10&rsquo;s Alu-Alu Blister pack<strong> </strong>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aljameah Street, Malaz quarter,   Riyadh 11441, Saudi Arabia Tel: 
+966 11 477 2215
Manufacture:  
Hetero Lab Limited Unit III, Hyderabad, India.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>